Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
RAMOS, Jessica Fernandes
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.66, article ID e11, 8p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.
Palavras-chave
Hepatitis C. Hematopoietic stem cell transplantation, Prevalence, Clinical outcome.
URI
https://observatorio.fm.usp.br/handle/OPI/58796
Referências
  1. Abdelbary H, 2020, J EGYPT NATL CANCER, V32, DOI 10.1186/s43046-020-0020-1
  2. Arai Y, 2016, BONE MARROW TRANSPL, V51, P96, DOI 10.1038/bmt.2015.205
  3. Benzaken AS, 2019, BRAZ J INFECT DIS, V23, P182
  4. Borchardt RA, 2014, WORLD J GASTROENTERO, V20, P2771, DOI 10.3748/wjg.v20.i11.2771
  5. Brasil. Agencia Nacional de Vigilancia Sanitaria, Hemovigilancia no Brasil: relatorio consolidado 2007-2015
  6. Brasil. Ministerio da Saude, 2021, Bol Epidemiol, P1
  7. Cacoub P, 2014, DIGEST LIVER DIS, V46, pS165, DOI 10.1016/j.dld.2014.10.005
  8. Cunningham HE, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13091
  9. de Almeida-Neto C, 2013, TRANSFUSION, V53, P827, DOI 10.1111/j.1537-2995.2012.03840.x
  10. de Latour RP, 2008, J HEPATOL, V48, P1008, DOI 10.1016/j.jhep.2008.03.003
  11. de Latour RP, 2004, BLOOD, V103, P1618, DOI 10.1182/blood-2003-06-2145
  12. El-Sayed MH, 2004, EUR J GASTROEN HEPAT, V16, P1347, DOI 10.1097/00042737-200412000-00019
  13. Francisci D, 2006, HAEMATOL-HEMATOL J, V91, P980
  14. Hamaguchi M, 2002, INT J HEMATOL, V75, P324, DOI 10.1007/BF02982051
  15. Ivantes CAP, 2004, BONE MARROW TRANSPL, V33, P1181, DOI 10.1038/sj.bmt.1704519
  16. KLINGEMANN HG, 1991, BLOOD, V78, P3306
  17. Kyvernitakis A, 2016, BIOL BLOOD MARROW TR, V22, P717, DOI 10.1016/j.bbmt.2015.12.010
  18. Levi JE, 2017, TRANSFUSION MED, V27, P286, DOI 10.1111/tme.12427
  19. Ljungman P, 2012, BONE MARROW TRANSPL, V47, P1217, DOI 10.1038/bmt.2011.238
  20. Locasciulli A, 2003, BONE MARROW TRANSPL, V31, P295, DOI 10.1038/sj.bmt.1703826
  21. Locasciulli A, 1999, TRANSPLANTATION, V68, P1486, DOI 10.1097/00007890-199911270-00010
  22. Mendes-Oliveira F, 2015, TRANSFUS APHER SCI, V53, P238, DOI 10.1016/j.transci.2015.05.003
  23. Monich AG, 2017, TRANSFUS APHER SCI, V56, P130, DOI 10.1016/j.transci.2016.10.007
  24. Vieira PCM, 2017, TRANSFUSION, V57, P1968, DOI 10.1111/trf.14146
  25. Musto P, 2002, CLIN LYMPHOMA, V3, P150, DOI 10.3816/CLM.2002.n.021
  26. Nakasone H, 2013, AM J HEMATOL, V88, P477, DOI 10.1002/ajh.23436
  27. Oliver NT, 2017, BONE MARROW TRANSPL, V52, P138, DOI 10.1038/bmt.2016.196
  28. Onodera K, 2021, J INFECT CHEMOTHER, V27, P1230, DOI 10.1016/j.jiac.2021.02.002
  29. Pessoni LL, 2019, HEMATOL TRANSF CELL, V41, P310, DOI 10.1016/j.htct.2019.03.009
  30. Piñana JL, 2016, TRANSPL INFECT DIS, V18, P89, DOI 10.1111/tid.12474
  31. Ramos CA, 2009, HAEMATOL-HEMATOL J, V94, P249, DOI 10.3324/haematol.13756
  32. Rauwolf K, 2019, J VIRAL HEPATITIS, V26, P454, DOI 10.1111/jvh.13046
  33. Shamsi TS, 2008, BONE MARROW TRANSPL, V42, pS114, DOI 10.1038/bmt.2008.137
  34. Silva Sônia Mara Nunes da, 2016, Rev. Bras. Hematol. Hemoter., V38, P206, DOI 10.1016/j.bjhh.2016.05.005
  35. Strasser SI, 1999, HEPATOLOGY, V29, P1893, DOI 10.1002/hep.510290609
  36. Tomás JF, 2000, BONE MARROW TRANSPL, V26, P649, DOI 10.1038/sj.bmt.1702532
  37. Torres HA, 2015, BIOL BLOOD MARROW TR, V21, P1870, DOI 10.1016/j.bbmt.2015.07.033
  38. United States of America. Department of Health and Human Services. National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS, 2017, Table for grading the severity of adult and pediatric adverse events
  39. World Health Organization (WHO), Hepatitis C
  40. Yakushijin K, 2016, BONE MARROW TRANSPL, V51, P403, DOI 10.1038/bmt.2015.283

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM